Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Monopar Therapeutics Inc(MNPR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MNPR
10/28/2026: MNPR (3-star) is currently NOT-A-BUY. Pass it for now.
Monopar Therapeutics is a clinical-stage biotechnology company focused on developing proprietary treatments to improve outcomes for cancer patients. Its main strengths include a lean, cost-efficient R&D model and a leadership team with deep oncology expertise. The primary growth opportunity lies in successfully advancing its lead candidates, including the promising next-generation drug Camsirubicin, toward commercialization. However, the company faces significant risks, including the binary nature of clinical trial results, high cash burn rates, and intense competition from much larger, better-funded entities. This stock is best suited for high-risk, growth-oriented investors who can monitor clinical milestones and the company’s capital runway closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to clinical breakthroughs, but lacks the established revenue growth typical of mature growth stocks. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunities during periods of clinical news, provided the stock displays strong technical trends. |
| Value investor | Weak fit | There are no traditional earnings or cash flow metrics to support a value-based investment thesis. |
| Dividend investor | Weak fit | Monopar does not pay dividends and focuses all capital on research and development. |
| Low-risk investor | Weak fit | The extreme volatility and binary risk associated with clinical trial outcomes make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical trial data, which can lead to significant intraday and long-term price swings. |
| Valuation risk | High | Valuation is based on speculative future outcomes rather than current financial performance, creating risk if milestones are missed. |
| Competition risk (Oncology biotech) | High | Large, well-funded incumbents can develop competing therapies that may render Monopar's programs obsolete. |
| Business quality | Medium | As a pre-revenue clinical company, the business is purely R&D focused, which lacks the stability of commercialized operations. |
| Dividend income | Low / none | The company provides no income to investors. |
| Execution risk | High | The company must successfully navigate complex regulatory paths and trial design to bring products to market. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 731.13% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 482.20M USD | Price to earnings Ratio - | 1Y Target Price 129.92 |
Price to earnings Ratio - | 1Y Target Price 129.92 | ||
Volume (30-day avg) 156.4K shares | Beta 1.51 | 52 Weeks Range 50.07 - 124.82 | Updated Date 10/28/2026 |
52 Weeks Range 50.07 - 124.82 | Updated Date 10/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.2 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Oncology Research & Development | Clinical trial advancement and intellectual property licensing of cancer therapeutics. | The company does not currently generate sales; value is driven by the potential success of its clinical trials. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 339.29M | Price to Sales(TTM) - |
Enterprise Value 339.29M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 6.71M | Shares Floating 4.47M |
Shares Outstanding 6.71M | Shares Floating 4.47M | ||
Percent Insiders 23.46 | Percent Institutions 94.92 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.